Publications by authors named "Thomas Kull"

Claim this Profile
Q
Quantitative and correlative biodistribution analysis of Zr-labeled mesoporous silica nanoparticles intravenously injected into tumor-bearing mice.
Larissa Kramer, Gordon Winter, Benjamin Baur, Andrea J Kuntz, Thomas Kull

Nanoscale· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chirurgische Behandlung von Melanomen in der Schwangerschaft: eine praktische Anleitung.
Diana Crisan, Nicolai Treiber, Thomas Kull, Peter Widschwendter, Oliver Adolph

J Dtsch Dermatol Ges· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical treatment of melanoma in pregnancy: a practical guideline.
Diana Crisan, Nicolai Treiber, Thomas Kull, Peter Widschwendter, Oliver Adolph

J Dtsch Dermatol Ges· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Peter Kletting, Thomas Kull, Christian Maaß, Noeen Malik, Markus Luster

J Nucl Med· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proposal of a computed tomography classification for hepatic alveolar echinococcosis.
Tilmann Graeter, Wolfgang Kratzer, Suemeyra Oeztuerk, Mark Martin Haenle, Richard Andrew Mason, Thomas Kull

World J Gastroenterol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Sven Norbert Reske, Gordon Winter, Benjamin Baur, Hans-Jürgen Machulla, Thomas Kull

Eur J Nucl Med Mol Imaging· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determination of individual organ masses for (90)Y-anti-CD66 radioimmunotherapy: influence on therapy planning.
Thomas Kull, P Kletting, S N Reske, Gerhard Glatting

Z Med Phys· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New molecular markers for prostate tumor imaging: a study on 2-methylene substituted fatty acids as new AMACR inhibitors.
Agnieszka Morgenroth, Elizaveta A Urusova, Cornelia Dinger, Ehab Al-Momani, Thomas Kull

Chemistry· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
Peter Kletting, Thomas Kull, Donald Bunjes, M Luster, Sven N Reske

Med Phys· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catalytic asymmetric synthesis of trans-configured beta-lactones: cooperation of Lewis acid and ion pair catalysis.
Thomas Kull, José Cabrera, René Peters

Chemistry· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model.
Peter Kletting, Thomas Kull, Donald Bunjes, Bettina Mahren, Markus Luster

J Nucl Med· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing time activity curves using the Akaike information criterion.
Peter Kletting, Thomas Kull, Sven N Reske, Gerhard Glatting

Phys Med Biol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biologic study of IV-14, a new ribonucleoside radiotracer for tumor visualization.
Boris D Zlatopolskiy, Agnieszka Morgenroth, Falk H-G Kunkel, Elizaveta A Urusova, Cornelia Dinger, Thomas Kull

J Nucl Med· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards to hENT1-nucleoside transporter selective imaging agents. Synthesis and in vitro evaluation of the radiolabeled SAENTA analogues.
Boris D Zlatopolskiy, Agnieszka Morgenroth, Elizaveta A Urusova, Cornelia Dinger, Thomas Kull

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.
Andreas K Buck, Martin Bommer, Malik E Juweid, Gerhard Glatting, Stephan Stilgenbauer, Thomas Kull

J Nucl Med· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferential tumor targeting and selective tumor cell cytotoxicity of 5-[131/125I]iodo-4'-thio-2'-deoxyuridine.
Agnieszka Morgenroth, Sandra Deisenhofer, Gerhard Glatting, Falk H-G Kunkel, Cornelia Dinger, Thomas Kull

Clin Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contact ion pair directed Lewis acid catalysis: asymmetric synthesis of trans-configured beta-lactones.
Thomas Kull, René Peters

Angew Chem Int Ed Engl· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal radionuclide therapy: The ULMDOS software for treatment planning.
Gerhard Glatting, Michael Landmann, Thomas Kull, Arthur Wunderlich, Norbert M Blumstein

Med Phys· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal radionuclide therapy: the ULMDOS software for treatment planning.
Gerhard Glatting, Michael Landmann, Thomas Kull, Arthur Wunderlich, Norbert M Blumstein

Med Phys· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode.
Thomas Kull, Jochen Ruckgaber, Rolf Weller, Sven Reske, Gerhard Glatting

Cancer Biother Radiopharm· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Inga Buchmann, Thomas Kull, Gerhard Glatting, Donald Bunjes, Geoffrey Hale

Eur J Nucl Med Mol Imaging· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis